First Tracks Reports Positive Early Trial Results for Celiac Drug ANB033
Early trial data show First Tracks’ ANB033 reduced intestinal damage and symptoms during a gluten challenge. Company plans late-stage development in 2027.
/ 2 items
Early trial data show First Tracks’ ANB033 reduced intestinal damage and symptoms during a gluten challenge. Company plans late-stage development in 2027.
Argenx acquires Forte Biosciences for $77/share, adding the first-in-class FB102 anti-CD122 antibody to expand its immunology pipeline for autoimmune diseases.